A double-blind, randomized, placebo-controlled study of atorvastatin as prevention of cerebrovascular events in patients with a previous transient ischemic attack (TIA) or stroke

Trial Profile

A double-blind, randomized, placebo-controlled study of atorvastatin as prevention of cerebrovascular events in patients with a previous transient ischemic attack (TIA) or stroke

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Jan 2017

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Atrial fibrillation; Coronary disorders; Stroke; Transient ischaemic attacks
  • Focus Therapeutic Use
  • Acronyms SPARCL
  • Sponsors Pfizer
  • Most Recent Events

    • 17 Jan 2017 Results of biomarker substudy along with main study published in the Journal of the American College of Cardiology
    • 17 Nov 2013 Results of a biomarker analysis presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 28 Jan 2010 Results published in Stroke : 28 Jan 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top